Canada Life
TPTX

Canada Life’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Canada Life’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,550
Closed -$192K – 2418
2022
Q2 		$192K Buy
2,550
+69
+3% +$3.07K ﹤0.01% 1824
2022
Q1 		$71K Buy
2,481
+88
+4% +$2.96K ﹤0.01% 2081
2021
Q4 		$114K Buy
2,393
+84
+4% +$3.76K ﹤0.01% 1979
2021
Q3 		$154K Hold
2,309
– – ﹤0.01% 1960
2021
Q2 		$180K Sell
2,309
-423
-15% -$31.3K ﹤0.01% 1947
2021
Q1 		$256K Hold
2,732
– – ﹤0.01% 1890
2020
Q4 		$332K Buy
2,732
+681
+33% +$74.6K ﹤0.01% 1849
2020
Q3 		$179K Hold
2,051
– – ﹤0.01% 1927
2020
Q2 		$132K Buy
2,051
+813
+66% +$46.9K ﹤0.01% 1990
2020
Q1 		$55K Hold
1,238
– – ﹤0.01% 2105
2019
Q4 		$77K Buy
+1,238
New +$58.9K ﹤0.01% 2136

Canada Life's TPTX Position: Q3 2022 in Review

Canada Life sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 2,550 shares — an estimated $192K sold.

Canada Life first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $332K in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Canada Life reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Canada Life sold 2,550 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $192K.
  • Canada Life first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Canada Life's Turning Point Therapeutics, Inc. Common Stock position peaked at $332K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Canada Life's 13F filing for Q3 2022, filed 1 Nov 2022.